Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 plus rapamycin in over-treated SLE
ChiCTR-IPR-16009451Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Nov 2016
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of aldesleukin and sirolimus in systemic lupus erythematosus (SLE) (3 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Efficacy endpoint (SLEDAI). Planned start Nov 2016; status: not yet recruiting.
02
Drugs
aldesleukinsirolimus
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR-IPR-16009451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009451.